Your IP Strategy & Patent Litigation Support Partner | Patent Research & Technology Intelligence Services| Patent Analysis Services
We help our medical device clients with technology intelligence services which is helpful to develop IP strategies. In addition, we provide research support to finalise the prototype of the Medical diagnostic kits. Over the years we have executed more than 100+ intellectual property research and analysis projects in the medical diagnostic domain.
Generally after analysing the patent results the decision makers are able to understand the market dynamics.
File a Patent Application for your Medical Device Invention. First, Protect your idea and never let someone else file first before patent office. Get your patent application reviewed by a Patent Attorney.
Applying & Filing Patents in Medical Device Sector. We draft description of patents and complete patent specifications in accordance with the latest patent law. We help Patenting your Invention, Idea, & Innovation worldwide. We also perform Patent Validity Search & Patent Invalidity Searches for your technology.
Getwell Oncology manufactures and markets Epirubicin Hydrochloride for Injection - Epiruba, and other range of complex generics and drug delivery based formulations at a cost effective price.
Discusses the available scope of patent protection for advances in diagnostics as well as the types of claims available in different jurisdictions. Additionally covers "support", i.e. the enabling teaching that is the trade-off for the patent monopoly, in the context of diagnostic patent applications. Finally, considers the enforcement and exploitation of patents directed to diagnostics.
Presenters: Anna Wilkinson and Cynthia Tape, Ogilvy Renault
File a Patent Application for your Medical Device Invention. First, Protect your idea and never let someone else file first before patent office. Get your patent application reviewed by a Patent Attorney.
Applying & Filing Patents in Medical Device Sector. We draft description of patents and complete patent specifications in accordance with the latest patent law. We help Patenting your Invention, Idea, & Innovation worldwide. We also perform Patent Validity Search & Patent Invalidity Searches for your technology.
Getwell Oncology manufactures and markets Epirubicin Hydrochloride for Injection - Epiruba, and other range of complex generics and drug delivery based formulations at a cost effective price.
Discusses the available scope of patent protection for advances in diagnostics as well as the types of claims available in different jurisdictions. Additionally covers "support", i.e. the enabling teaching that is the trade-off for the patent monopoly, in the context of diagnostic patent applications. Finally, considers the enforcement and exploitation of patents directed to diagnostics.
Presenters: Anna Wilkinson and Cynthia Tape, Ogilvy Renault
To know the trends in patent filing in India in the field of probiotics, a detailed search was performed at the official website for the granted patents and the published applications. Presented here is the summary of the trends.
Medical Device Patent Sector in India | Patent Invalidation Services | Patent Landscape Study for Granted Patents in Cardiac Stents Medical Device Category in India
Our patent attorneys provide plaintiffs or defendants with patent validity / patent invalidity searches which are very handy for ongoing patent litigation before the US court. Generally, patent validity search / patent invalidity searches are conducted by the patent attorney after a patent is granted by the patent office.
The patent validity search or patent invalidity searches is a detailed prior art patent search which takes into the consideration of the priority filling date of the patent to be invalidated. The main aim to perform patent validity search or patent invalidity searches is validate the enforceability of the granted patent claims or to invalidate one or more patent claims of a patent invention.
The main aim to perform patent validity search or patent invalidity searches is validate the enforceability of the granted patent claims or to invalidate one or more patent claims of a patent invention.
11 years old presentation submitted as Project work: Golden Mantra to Perform Worldwide Patent Searches
Patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, usually 20 years from the filing date. A patent is, in effect, a limited property right that the government offers to inventors in exchange for their agreement to share the details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
In order to obtain a patent, an applicant must provide a written description of his or her invention in sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention.
Capsule Endoscopy Patent Landscape Flyer 2014
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule
endoscopy IP and the relative strength of
their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
PATENTING AND REGULATORY REQUIREMENTS OF NATURAL PRODUCTS
PROTECTION OF PLANT VARIETIES AND FARMERS' RIGHTS ACT, 2001
BIOPROSPECTING AND BIOPIRACY
PATENTING ASPECTS OF TRADITIONAL KNOWLEDGE AND NATURAL PRODUCTS. CASE STUDY OF
CURCUMA & NEEM
Dr. David Edwards - Animal Biotechnology: Innovation Stifled by InactionJohn Blue
Animal Biotechnology: Innovation Stifled by Inaction - David Edwards, PhD Director, Biotechnology Industry Organization, from the 2014 NIAA Annual Conference titled 'The Precautionary Principle: How Agriculture Will Thrive', March 31 - April 2, 2014, Omaha, NE, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2014_niaa_how_animal_agriculture_will_thrive
Brief report on coronavirus by incubigAnkit Lekhra
Read the report by Incubig to know more about this deadly virus and understand the efforts of the global research community for providing treatment for this pathogenic virus, for which prior treatment did not exist and potential for a pandemic remains.
Coronavirus outbreak already at a pandemic level. The economy can be revived, but what about the lost lives? We need a unified global effort to save the lives of millions.
Our team at Incubig will regularly publish research activity by the worldwide universities, and organizations under coronavirus, specifically for finding the vaccine for this deadly virus.
Reach out to us at contact@incubig.com for more details.
Thank you.
Incubig
Accelerating innovation | www.incubig.com
https://www.blockchainailawyer.com/iprs Oracle Database is a trademark of Oracle Corporation, which is a leading provider of database software and cloud services. Oracle Database trademark applications are the legal documents that seek to register and protect the Oracle Database brand name and logo in various jurisdictions around the world.
Migrating Oracle Database trademark applications to cloud infrastructure means moving the data and processes related to these applications from on-premises servers or other cloud platforms to Oracle Cloud Infrastructure (OCI), which is Oracle’s next-generation cloud platform that offers high performance, security, scalability, and cost-efficiency for various workloads.
There are several advantages of migrating Oracle Database trademark applications to cloud infrastructure, such as:
Reducing the operational and maintenance costs of managing on-premises servers or other cloud platforms
Leveraging the advanced features and services of OCI, such as autonomous database, data management, analytics, integration, security, and identity
Enhancing the availability, reliability, and performance of the trademark applications and data
Simplifying the compliance and governance of the trademark applications and data across different regions and jurisdictions
Accelerating the innovation and development of new trademark applications and services
There are different methods and tools for migrating Oracle Database trademark applications to cloud infrastructure, depending on the source and target environments, the size and complexity of the data, and the migration objectives and requirements. Some of the common methods and tools are:
Oracle Data Pump: A utility that enables the export and import of data and metadata between Oracle databases, either on-premises or on OCI
Oracle GoldenGate: A software solution that enables the replication and synchronization of data and transactions across heterogeneous databases, either on-premises or on OCI
Oracle Zero Downtime Migration: A tool that automates the migration of Oracle databases from on-premises or other cloud platforms to OCI, with minimal or no downtime
Oracle Cloud Infrastructure Database Migration: A fully-managed service that provides a high-performing, self-service experience for migrating Oracle databases from on-premises, Oracle Cloud, or Amazon RDS to OCI
For more information about migrating Oracle Database trademark applications to cloud infrastructure, you can refer to the following resources:
Overview of Oracle Cloud Infrastructure Database Migration
About the Advantages of Migrating Custom Applications to Oracle Cloud
Learn about migrating Oracle Database Appliance workloads to the cloud
Learn About Migrating Application Data to the Cloud
METHOD AND SYSTEM FOR PREDICTING OPTIMAL LOAD FOR WHICH THE YIELD IS
MAXIMUM BY USING MULTIPLE INPUT ELECTROLYZER PARAMETERS filed by RIPIK TECHNOLOGY PRIVATE LIMITED
This patent describes a system to optimize operations in manufacturing facilities that use electrolyzers. Electrolyzers split water into hydrogen and oxygen using electricity. Their electrical load levels impact costs and efficiency.
The present invention uses AI and machine learning to predict the best way to allocate load across multiple electrolyzers. This maximizes total yield for the manufacturing plant while minimizing electricity costs.
It takes into account equipment factors like the capacity of each electrolyzer. It also considers constraints like raw material supply and product storage limits. The system models chlorine evacuation too since that can hinder caustic soda output.
The algorithms are capable of processing the many complex variables at play. No easy spreadsheet could accomplish this modeling. A type of mathematical optimization called "swarm optimization" is applied. Examples are genetic algorithms and particle swarm optimization.
The AI system keeps adapting its load recommendations based on data coming into its monitoring dashboard. Operators can customize certain parameters but the software is configuring most of the decision logic automatically.
The inventors claim results show their AI optimizer significantly cutting power consumption and costs versus alternatives. Smart coordination of multiple electrolyzers is complex. This technology handles the data analysis to efficiently divide load distribution.
In essence, the patent discloses an intelligent electrolyzer load prediction platform. It leverages AI to boost manufacturing performance while reducing electricity usage. Company managers can see optimized operations guidance on easy dashboard interfaces. It aims to save power, costs and effort through algorithmic process coordination.
More Related Content
Similar to Patent Landscape & Technical IP Report for Antibody Antigen based Medical Diagnostic Kits filed in India
To know the trends in patent filing in India in the field of probiotics, a detailed search was performed at the official website for the granted patents and the published applications. Presented here is the summary of the trends.
Medical Device Patent Sector in India | Patent Invalidation Services | Patent Landscape Study for Granted Patents in Cardiac Stents Medical Device Category in India
Our patent attorneys provide plaintiffs or defendants with patent validity / patent invalidity searches which are very handy for ongoing patent litigation before the US court. Generally, patent validity search / patent invalidity searches are conducted by the patent attorney after a patent is granted by the patent office.
The patent validity search or patent invalidity searches is a detailed prior art patent search which takes into the consideration of the priority filling date of the patent to be invalidated. The main aim to perform patent validity search or patent invalidity searches is validate the enforceability of the granted patent claims or to invalidate one or more patent claims of a patent invention.
The main aim to perform patent validity search or patent invalidity searches is validate the enforceability of the granted patent claims or to invalidate one or more patent claims of a patent invention.
11 years old presentation submitted as Project work: Golden Mantra to Perform Worldwide Patent Searches
Patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, usually 20 years from the filing date. A patent is, in effect, a limited property right that the government offers to inventors in exchange for their agreement to share the details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
In order to obtain a patent, an applicant must provide a written description of his or her invention in sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention.
Capsule Endoscopy Patent Landscape Flyer 2014
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule
endoscopy IP and the relative strength of
their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
PATENTING AND REGULATORY REQUIREMENTS OF NATURAL PRODUCTS
PROTECTION OF PLANT VARIETIES AND FARMERS' RIGHTS ACT, 2001
BIOPROSPECTING AND BIOPIRACY
PATENTING ASPECTS OF TRADITIONAL KNOWLEDGE AND NATURAL PRODUCTS. CASE STUDY OF
CURCUMA & NEEM
Dr. David Edwards - Animal Biotechnology: Innovation Stifled by InactionJohn Blue
Animal Biotechnology: Innovation Stifled by Inaction - David Edwards, PhD Director, Biotechnology Industry Organization, from the 2014 NIAA Annual Conference titled 'The Precautionary Principle: How Agriculture Will Thrive', March 31 - April 2, 2014, Omaha, NE, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2014_niaa_how_animal_agriculture_will_thrive
Brief report on coronavirus by incubigAnkit Lekhra
Read the report by Incubig to know more about this deadly virus and understand the efforts of the global research community for providing treatment for this pathogenic virus, for which prior treatment did not exist and potential for a pandemic remains.
Coronavirus outbreak already at a pandemic level. The economy can be revived, but what about the lost lives? We need a unified global effort to save the lives of millions.
Our team at Incubig will regularly publish research activity by the worldwide universities, and organizations under coronavirus, specifically for finding the vaccine for this deadly virus.
Reach out to us at contact@incubig.com for more details.
Thank you.
Incubig
Accelerating innovation | www.incubig.com
Similar to Patent Landscape & Technical IP Report for Antibody Antigen based Medical Diagnostic Kits filed in India (20)
https://www.blockchainailawyer.com/iprs Oracle Database is a trademark of Oracle Corporation, which is a leading provider of database software and cloud services. Oracle Database trademark applications are the legal documents that seek to register and protect the Oracle Database brand name and logo in various jurisdictions around the world.
Migrating Oracle Database trademark applications to cloud infrastructure means moving the data and processes related to these applications from on-premises servers or other cloud platforms to Oracle Cloud Infrastructure (OCI), which is Oracle’s next-generation cloud platform that offers high performance, security, scalability, and cost-efficiency for various workloads.
There are several advantages of migrating Oracle Database trademark applications to cloud infrastructure, such as:
Reducing the operational and maintenance costs of managing on-premises servers or other cloud platforms
Leveraging the advanced features and services of OCI, such as autonomous database, data management, analytics, integration, security, and identity
Enhancing the availability, reliability, and performance of the trademark applications and data
Simplifying the compliance and governance of the trademark applications and data across different regions and jurisdictions
Accelerating the innovation and development of new trademark applications and services
There are different methods and tools for migrating Oracle Database trademark applications to cloud infrastructure, depending on the source and target environments, the size and complexity of the data, and the migration objectives and requirements. Some of the common methods and tools are:
Oracle Data Pump: A utility that enables the export and import of data and metadata between Oracle databases, either on-premises or on OCI
Oracle GoldenGate: A software solution that enables the replication and synchronization of data and transactions across heterogeneous databases, either on-premises or on OCI
Oracle Zero Downtime Migration: A tool that automates the migration of Oracle databases from on-premises or other cloud platforms to OCI, with minimal or no downtime
Oracle Cloud Infrastructure Database Migration: A fully-managed service that provides a high-performing, self-service experience for migrating Oracle databases from on-premises, Oracle Cloud, or Amazon RDS to OCI
For more information about migrating Oracle Database trademark applications to cloud infrastructure, you can refer to the following resources:
Overview of Oracle Cloud Infrastructure Database Migration
About the Advantages of Migrating Custom Applications to Oracle Cloud
Learn about migrating Oracle Database Appliance workloads to the cloud
Learn About Migrating Application Data to the Cloud
METHOD AND SYSTEM FOR PREDICTING OPTIMAL LOAD FOR WHICH THE YIELD IS
MAXIMUM BY USING MULTIPLE INPUT ELECTROLYZER PARAMETERS filed by RIPIK TECHNOLOGY PRIVATE LIMITED
This patent describes a system to optimize operations in manufacturing facilities that use electrolyzers. Electrolyzers split water into hydrogen and oxygen using electricity. Their electrical load levels impact costs and efficiency.
The present invention uses AI and machine learning to predict the best way to allocate load across multiple electrolyzers. This maximizes total yield for the manufacturing plant while minimizing electricity costs.
It takes into account equipment factors like the capacity of each electrolyzer. It also considers constraints like raw material supply and product storage limits. The system models chlorine evacuation too since that can hinder caustic soda output.
The algorithms are capable of processing the many complex variables at play. No easy spreadsheet could accomplish this modeling. A type of mathematical optimization called "swarm optimization" is applied. Examples are genetic algorithms and particle swarm optimization.
The AI system keeps adapting its load recommendations based on data coming into its monitoring dashboard. Operators can customize certain parameters but the software is configuring most of the decision logic automatically.
The inventors claim results show their AI optimizer significantly cutting power consumption and costs versus alternatives. Smart coordination of multiple electrolyzers is complex. This technology handles the data analysis to efficiently divide load distribution.
In essence, the patent discloses an intelligent electrolyzer load prediction platform. It leverages AI to boost manufacturing performance while reducing electricity usage. Company managers can see optimized operations guidance on easy dashboard interfaces. It aims to save power, costs and effort through algorithmic process coordination.
The U.S. Food and Drug Administration (USFDA) regulates the use of food additives in the United States. Specifically, food additives are subject to regulation under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the regulations in Title 21 of the Code of Federal Regulations (21 CFR). These regulations define the conditions under which food additives, including acidity regulators like Orthophosphoric acid (Phosphoric Acid), can be used in food and beverages.
The specific regulations and allowable levels of Orthophosphoric acid in food and beverages, including gold drinks, can be found in the Code of Federal Regulations (21 CFR) Title 21, Part 182, which deals with substances generally recognized as safe (GRAS) for use in food. Orthophosphoric acid is covered in the section "21 CFR 182.1073 - Phosphoric acid" and its use in various food categories is outlined in this regulation.
For precise information on the allowable levels of Orthophosphoric acid in gold drinks or any other food and beverage products in the United States, it is advisable to refer to the specific regulations provided in 21 CFR 182.1073 and consult with the U.S. Food and Drug Administration (USFDA) or their official resources to ensure compliance with the most up-to-date regulations.
https://sciwri.club/archives/4288
Prity Khastgir is a techno-savvy patent attorney in India with 12 yrs of experience working with clients across the globe. Her areas of expertise are IP portfolio research, cross-border technology transactions, licensing agreements, product clearance, freedom-to-operate, patent infringement & invalidity analysis, research & opinions. Currently, she helps startups to raise funds, assists foreign companies to find right business partners in India. She also assists enterprises to enter and find the right angels, and VCs in Malaysia, Singapore, US, UK, Japan and India. Here, she answers questions about IP career prospects in India, in her Face-to-face interaction with Reetu Mehta.
Is Intellectual Property Rights (IPR) a good career option in India?
Before answering this question, I ask myself why I do what I do every morning. Am I passionate about my day? IPR is a fascinating field and apt for people who wants answers to questions related to what, why, when and how. IPR is a field of law protecting creations of mind in form of ideas, inventions, brands, trademarks, copyrights, software codes, industrial design registration and trade secrets. However, if research is not your cup of tea then please do not enter this field. You have to passionate about innovations. Many people enter this field because it is a high paying job in the long run compared to normal 9-5 jobs in India. However, not everyone will be able to sustain in this field in the long run. Therefore, be wise before entering this field. You should be fascinated by technologies around you, have a problem solving approach, and be compassionate towards your peers.
How can a life science PhD begin with career in IPR?
Life science is study of life processes. The scope of PhD in IPR is better as the person is familiar with research. The best way to move forward is to do online IPR courses and get an overview of IPR. One should have interest and passion to solve the queries related to the intellectual creations of mind. One should have problem solving approach as client is looking for solutions.
What are the required skill sets?
First and foremost, the person should have technology and legal acumen to understand innovations and have a research capability to work at least for 10-12 hours. Thinking out of the box to solve a research project is the key to assisting inventors to protect their inventions.
How does a career in IP evolve/grow in India?
The individuals I have come across are passionate about protecting innovations. To evolve in this field you have to be technology savvy. The Intellectual Property law has evolved a lot in last 10 years. Now a trademark can be registered in less than one month in India with proper documentation. The Indian government is giving a number of grants to startups in India to grow by leap and bounds.
What is the kind of work one is expected to do and what are the skill sets one can acquire over the course?
Trade Secret as Intellectual Property Strategic
Tool in Industry 4.0
Prity Khastgir
TCIS India, Level-5, Caddie Commercial Tower, Novotel Hotel, Hospitality District Aerocity,
IGI Airport, New Delhi 110037 India
khasip@khastgir.com
Abstract -- In covid situation, most businesses have reviewed
their existing contracts to understand scope of parties involved
and thereby Intellectual Property clauses and sub-clauses of any
contract or agreement become very important. Private blockchain
implementation in the current scenario is key to the maze to
protect trade secrets in a confidential manner.
Progressive IP strategy and partnering with right partners to
create and maintain sustainable development positions in the
market to serve customers and catering to their needs is the need
of the hour. Proactive strategic signed contracts and agreements
should be mandatory for smooth functioning of any start-up or
enterprise. Negotiation, Mediation and Arbitration are like trinity
in law to resolve any arising conflict.
Keywords: Intellectual Property, Trade secrets protection, Blockchain
implementation, Industry 4.0, Public domain
I. INTRODUCTION
EVERY technology launch contributes to macroeconomic
growth of the country. Contracts and agreements drafted around
technology licensing or assignments play a pivotal role as to
how developed innovation would be deployed in different
verticals. Over the last one decade, we have witnessed a very
strong nonlinear curve and especially with what forms part of
terms and conditions to exert control over under applicable
contract law while collaborating with different parties to
manage successful ventures in Industry 4.0 operating in
multiple jurisdictions and protecting trade secrets.
Primarily, contracts and proper agreements in place sets the
ambit right to protect trade secrets of technology driven startup ventures. Understanding Intellectual property landscape and
conducting IP due-diligence is very important and is essentially
a first step to understand short-term and long-term goals to
prepare rock solid IP strategy with a holistic viewpoint.
Intellect is the creation of the mind and protecting intellectual
capacity by utilizing different IPRs is key to deliver market cap
results. In covid situation, most businesses have reviewed their
existing contracts to understand scope of parties involved and
thereby Intellectual Property clauses and sub-clauses of any
t's quite unfair because laundering is taking place either domestic investors we can even take place by foreign investors. What kind of modification we could have done? Now you case capital investors of foreign investors what they have. Some of you are still asking me how do you calculate here. Fair market value for calculation is by a book value method or discounted cash flow method. In order to see examples of beginning for examination, basically calculate the fair market value. So you can see new budget proposal is applicable to capital raise from both as well as foreign. Taxi. Number 21. Venture capitalists and Angel investors are both safe. Companies considered startups were approved. Five years annual turnover? Not usually. The Startup India scheme is implemented by Ministry of Commerce and Industry. There is indeed implemented by Minister. No. The Angel Tax has been introduced for the first time in amendment to Income Tax Act. For the first time, Angel Tax is applicable to both Mr. and Mr. Companies. And the Angel facts made applicable to capital raised for more domestic and foreign investors kits. And there's investors now it is for both. This quarter. This tax is imposed only when the startup company is issuing shares at a price on the fair market price. It's a startup companies raising capital at a fair market value added taxes. The tax on long term debt. So recently the government has made certain changes to the spec long term capital gains tax on debt. Take this on long term capital gains tax on deposits. Let's look at this more capital gains. What is capital gains? Capital gains tax is the tax which people pay on profits which they make by selling. And whenever I sell an asset begin profit a part of that profit paid to commit tax capital gains, for example. I want to share at least in the year 15. I have shared and made a mistake to comment says if you have made pocket. Is capital gains tax will come into play if you make a loss? Your losses. Understand this concept of what is long term comes against that. Which takes money from investors and after taking money from investors, that money is invested in different different financial shares. So here we have predominantly more types of. Mutual funds are those funds. There mutual funds are investing more than 65% money in checks that mutual funds are. More than 65% of money is invested in bonds, which means it pretty much the funds can make investment in shares. Bonds. But where is the priority investment shares? They can make investment in both shares and bonds. Investment. On the equity mutual funds, we have short term capital gains tax and long term capital gains. Short term capital gains tax comes into play if I buy and sell. Long term capital gains tax will come into play if I buy and sell after. Play. March 2023, just in one year. And sending. You can. And. What is long term Complications? They're 2023. I bought it in March 2024. After more than one year. How much is it? Capital
xtell. Why September the 26th, I don't have a good picture, but I know for the first half the intelligence was saying it's gonna be a long war. He decided then to do it, and he had set it up so he could just say yes and a day later would blow away. You said it and say work by sonars. Frequency, you can blow them up, you can do it. So tough thing to do. And so why at that point, whether he was deciding is this is going to be a long war, it's going to cost a lot of money. I'm going to go all the way. He's now moving a lot of American troops and equipment into Poland. I don't know if he's going to commit native to it. I don't know if NATO wants to go, but he basically gave Chancellor Schultz, took away the option of Schultz to say I'm going to stop giving them arms. Winter's coming. I want that pipeline. I want to keep my people warm and wealthy. So he blew it up. So there's been a lot of news reporting, a lot of interest on this very simple question. Who blew up the North Stream pipelines? Remember in September of last year, the North Stream One and N Stream Two, which are two parallelly running pipelines carrying natural gas from Russia to Germany, were blown up. There were massive explosions which happened 250 feet are below the sea. Now the first report that came out, which was last month by a famous American journalist, which seemed to suggest that this was an inside job, it was carried out by the United States using state actors. now just this past week there's been some follow up reporting
September the 26th last year and. I there was no way. Common sense. You have to deal with common sense. Well, let's see. I knew that no Russia would have done it because of Putin already had responded. There's two major pipelines, N Stream one, which has been alive for since 2011, and Nord Stream two, which is. These are huge. They moved millions of whatever the measurement is of natural gas. There is a different measurement and it's not cubic feet, it's they they they move in, they mouth stream one turn Germany because they supplied cheap natural gas. That was very clear. Then they needed it anyway. I'm just giving you all this because I'm not here. I can answer your question, but I be coming from the blue one. I don't want to come from the blue. I want people to understand I've done this a long time. So the White House, Mr. Hush, they have rejected your story outright. They've called it a figment of your imagination. More fiction than fact is the wording that they used. Germany has also taken a very cautious mind on your story. You referred before in your first answer to Western media like the New York Times, The Washington Post. Had you taken your story to the editors there, would they have published such a consequential story basis, Just one single, unnamed anonymous source? How would you react to that? This source? Would I the way described the story and the intent of how I sourced it? Was to be as as vague as possible. It would have
Play with Data aka Magic
tell. Why September the 26th, I don't have a good picture, but I know for the first half the intelligence was saying it's gonna be a long war. He decided then to do it, and he had set it up so he could just say yes and a day later would blow away. You said it and say work by sonars. Frequency, you can blow them up, you can do it. So tough thing to do. And so why at that point, whether he was deciding is this is going to be a long war, it's going to cost a lot of money. I'm going to go all the way. He's now moving a lot of American troops and equipment into Poland. I don't know if he's going to commit native to it. I don't know if NATO wants to go, but he basically gave Chancellor Schultz, took away the option of Schultz to say I'm going to stop giving them arms. Winter's coming. I want that pipeline. I want to keep my people warm and wealthy. So he blew it up. So there's been a lot of news reporting, a lot of interest on this very simple question. Who blew up the North Stream pipelines? Remember in September of last year, the North Stream One and N Stream Two, which are two parallelly running pipelines carrying natural gas from Russia to Germany, were blown up. There were massive explosions which happened 250 feet are below the sea. Now the first report that came out, which was last month by a famous American journalist, which seemed to suggest that this was an inside job, it was carried out by the United States using state actors. now just this past week there's been some follow up reporting
September the 26th last year and. I there was no way. Common sense. You have to deal with common sense. Well, let's see. I knew that no Russia would have done it because of Putin already had responded. There's two major pipelines, N Stream one, which has been alive for since 2011, and Nord Stream two, which is. These are huge. They moved millions of whatever the measurement is of natural gas. There is a different measurement and it's not cubic feet, it's they they they move in, they mouth stream one turn Germany because they supplied cheap natural gas. That was very clear. Then they needed it anyway. I'm just giving you all this because I'm not here. I can answer your question, but I be coming from the blue one. I don't want to come from the blue. I want people to understand I've done this a long time. So the White House, Mr. Hush, they have rejected your story outright. They've called it a figment of your imagination. More fiction than fact is the wording that they used. Germany has also taken a very cautious mind on your story. You referred before in your first answer to Western media like the New York Times, The Washington Post. Had you taken your story to the editors there, would they have published such a consequential story basis, Just one single, unnamed anonymous source? How would you react to that? This source? Would I the way described the story and the intent of how I sourced it? Was to be as as vague as possible.
I know which you know. What is left? So I can close my eyes and enter into this and reach my office. So on a more serious note, I think. You cannot classify it as a treatment team or a team or you know, limited over 50. See Virat Kohli is good in 20, is good in limited over 20 Cricket is also good in Test cricket. So the RBI has to function and perform those fifty over match as well as in our effort. On effort and endeavor is always to optimize our for us to the best thing to extend that we can we put our best foot forward. Thank you very much. Thank you very much for accepting our condition. Great pleasure talking to you. Thank you very much and thank you very much for your patience. For short the time primarily for my longest answers. I can see your colleagues are very very efficient. But thank you once again. Thank you very much for your time. Thank you so much, Governor, and thank you again. Right for our next session. Welcome everyone And there's been talk about. Exciting transformations over the next several years will be the advent of Fight Jail India and this whole idea that India had. Physical. And it is an absolute delight to welcome for this fireside conversation to the Business Today India 100 Country Summit, one of the legendary. This generation. Quality and it's still standing fighting scale this in this fight can they have a popular as he walked through this Business Today and they have. Thank you so much. i want to start by asking you about the hearing which is about 5G everyone watching want We start at what does this mean? Everyone was listening to this. Fighting. And if you really look at the world fighting at most time to take roots, you know most of the Western world, Southeast Asian countries, Singapore and starts right as well I think we are some people think. Check this the perfect time some use cases. You can see devices coming through Priceline devices trying to find one perfectly from the country they can do so. I think we are ready. Thankfully this time the government put up a lot of spectrum because 5G requires made large chunks of spectrum to be effective. Otherwise they don't really get the joy of our friendship and not only the mid band which the seed bank claims. They're All in all, I think India is now ready from the spectrum point of view, but it's now standard and available. We have been building from this day for the last 24 months and predicted that we would want sometimes some of the preparedness felt that would probably come in 2021. But I think they're just takes time to develop the ecosystem. So we are ready. Expect launches October Believe will be from very early in October. Sometime in October you can start to see on your phones if there are any. We'll start with dictionaries, the key towns and the keep on as we've seen here earlier, keep on with right across and going into deep. What should you do to us, I mean today? Customer. Very important use cases which are developing around which took my mind are
tell. Why September the 26th, I don't have a good picture, but I know for the first half the intelligence was saying it's gonna be a long war. He decided then to do it, and he had set it up so he could just say yes and a day later would blow away. You said it and say work by sonars. Frequency, you can blow them up, you can do it. So tough thing to do. And so why at that point, whether he was deciding is this is going to be a long war, it's going to cost a lot of money. I'm going to go all the way. He's now moving a lot of American troops and equipment into Poland. I don't know if he's going to commit native to it. I don't know if NATO wants to go, but he basically gave Chancellor Schultz, took away the option of Schultz to say I'm going to stop giving them arms. Winter's coming. I want that pipeline. I want to keep my people warm and wealthy. So he blew it up. So there's been a lot of news reporting, a lot of interest on this very simple question. Who blew up the North Stream pipelines? Remember in September of last year, the North Stream One and N Stream Two, which are two parallelly running pipelines carrying natural gas from Russia to Germany, were blown up. There were massive explosions which happened 250 feet are below the sea. Now the first report that came out, which was last month by a famous American journalist, which seemed to suggest that this was an inside job, it was carried out by the United States using state actors. now just this past week there's been some follow up reporting
September the 26th last year and. I there was no way. Common sense. You have to deal with common sense. Well, let's see. I knew that no Russia would have done it because of Putin already had responded. There's two major pipelines, N Stream one, which has been alive for since 2011, and Nord Stream two, which is. These are huge. They moved millions of whatever the measurement is of natural gas. There is a different measurement and it's not cubic feet, it's they they they move in, they mouth stream one turn Germany because they supplied cheap natural gas. That was very clear. Then they needed it anyway. I'm just giving you all this because I'm not here. I can answer your question, but I be coming from the blue one. I don't want to come from the blue. I want people to understand I've done this a long time. So the White House, Mr. Hush, they have rejected your story outright. They've called it a figment of your imagination. More fiction than fact is the wording that they used. Germany has also taken a very cautious mind on your story. You referred before in your first answer to Western media like the New York Times, The Washington Post. Had you taken your story to the editors there, would they have published such a consequential story basis, Just one single, unnamed anonymous source? How would you react to that? This source? Would I the way described the story and the intent of how I sourced it? Was to be as as vague as possible. It would have been very
tell. Why September the 26th, I don't have a good picture, but I know for the first half the intelligence was saying it's gonna be a long war. He decided then to do it, and he had set it up so he could just say yes and a day later would blow away. You said it and say work by sonars. Frequency, you can blow them up, you can do it. So tough thing to do. And so why at that point, whether he was deciding is this is going to be a long war, it's going to cost a lot of money. I'm going to go all the way. He's now moving a lot of American troops and equipment into Poland. I don't know if he's going to commit native to it. I don't know if NATO wants to go, but he basically gave Chancellor Schultz, took away the option of Schultz to say I'm going to stop giving them arms. Winter's coming. I want that pipeline. I want to keep my people warm and wealthy. So he blew it up. So there's been a lot of news reporting, a lot of interest on this very simple question. Who blew up the North Stream pipelines? Remember in September of last year, the North Stream One and N Stream Two, which are two parallelly running pipelines carrying natural gas from Russia to Germany, were blown up. There were massive explosions which happened 250 feet are below the sea. Now the first report that came out, which was last month by a famous American journalist, which seemed to suggest that this was an inside job, it was carried out by the United States using state actors. now just this past week there's been some follow up reporting
September the 26th last year and. I there was no way. Common sense. You have to deal with common sense. Well, let's see. I knew that no Russia would have done it because of Putin already had responded. There's two major pipelines, N Stream one, which has been alive for since 2011, and Nord Stream two, which is. These are huge. They moved millions of whatever the measurement is of natural gas. There is a different measurement and it's not cubic feet, it's they they they move in, they mouth stream one turn Germany because they supplied cheap natural gas. That was very clear. Then they needed it anyway. I'm just giving you all this because I'm not here. I can answer your question, but I be coming from the blue one. I don't want to come from the blue. I want people to understand I've done this a long time. So the White House, Mr. Hush, they have rejected your story outright. They've called it a figment of your imagination. More fiction than fact is the wording that they used. Germany has also taken a very cautious mind on your story. You referred before in your first answer to Western media like the New York Times, The Washington Post. Had you taken your story to the editors there, would they have published such a consequential story basis, Just one single, unnamed anonymous source? How would you react to that? This source? Would I the way described the story and the intent of how I sourced it? Was to be as as vague as possible. It would have been
tell. Why September the 26th, I don't have a good picture, but I know for the first half the intelligence was saying it's gonna be a long war. He decided then to do it, and he had set it up so he could just say yes and a day later would blow away. You said it and say work by sonars. Frequency, you can blow them up, you can do it. So tough thing to do. And so why at that point, whether he was deciding is this is going to be a long war, it's going to cost a lot of money. I'm going to go all the way. He's now moving a lot of American troops and equipment into Poland. I don't know if he's going to commit native to it. I don't know if NATO wants to go, but he basically gave Chancellor Schultz, took away the option of Schultz to say I'm going to stop giving them arms. Winter's coming. I want that pipeline. I want to keep my people warm and wealthy. So he blew it up. So there's been a lot of news reporting, a lot of interest on this very simple question. Who blew up the North Stream pipelines? Remember in September of last year, the North Stream One and N Stream Two, which are two parallelly running pipelines carrying natural gas from Russia to Germany, were blown up. There were massive explosions which happened 250 feet are below the sea. Now the first report that came out, which was last month by a famous American journalist, which seemed to suggest that this was an inside job, it was carried out by the United States using state actors. now just this past week there's been some follow up reporting
September the 26th last year and. I there was no way. Common sense. You have to deal with common sense. Well, let's see. I knew that no Russia would have done it because of Putin already had responded. There's two major pipelines, N Stream one, which has been alive for since 2011, and Nord Stream two, which is. These are huge. They moved millions of whatever the measurement is of natural gas. There is a different measurement and it's not cubic feet, it's they they they move in, they mouth stream one turn Germany because they supplied cheap natural gas. That was very clear. Then they needed it anyway. I'm just giving you all this because I'm not here. I can answer your question, but I be coming from the blue one. I don't want to come from the blue. I want people to understand I've done this a long time. So the White House, Mr. Hush, they have rejected your story outright. They've called it a figment of your imagination. More fiction than fact is the wording that they used. Germany has also taken a very cautious mind on your story. You referred before in your first answer to Western media like the New York Times, The Washington Post. Had you taken your story to the editors there, would they have published such a consequential story basis, Just one single, unnamed anonymous source? How would you react to that? This source? Would I the way described the story and the intent of how I sourced it? Was to be as as vague as possible. It would have been very
AboutAbout
As a Machine Learning Engineer, I am enthusiastic about exploring the fascinating field of machine learning and its potential applications in solving real-world problems. I have a good amount of knowledge in mathematics, statistics, and computer science, which enables me to understand and implement the fundamental concepts and techniques of machine learning.
My experience includes working with various data analytics tools and technologies, such as SQL, Python, Tableau, and Power BI. I have developed expertise in data cleaning and exploratory data analysis, statistical inference, and machine learning techniques such as regression, and clustering, my experience also includes working with a variety of machine learning tools and frameworks, including, Scikit-learn, TensorFlow and Keras. I have also developed expertise in data pre-processing, feature engineering, and model selection, which has enabled me to create robust and accurate machine-learning models.
I am eager to expand my knowledge and expertise in machine learning research and AI-related fields. I am a quick learner, and I am always willing to take on new challenges and stretch myself to develop new skills. Furthermore, I am a good communicator and collaborator, able to work effectively in a team and learn from more experienced colleagues.
I am excited about the potential of machine learning to create positive change and improve people's lives specifically in Health Care industries. I am committed to staying up-to-date with the latest developments in machine learning and related fields, attending conferences and workshops, and engaging in continuous learning. I am eager to apply my skills and experience to solve complex problems and create value for organizations.
https://www.linkedin.com/in/sudharmendra-gv-7214361b2/
Machine Learning EngineerMachine Learning Engineer
Longevity InTime BioTech · Part-timeLongevity InTime BioTech · Part-time
Nov 2022 - Present · 6 mosNov 2022 - Present · 6 mos
Wilmington, Delaware, United StatesWilmington, Delaware, United States
Longevity Intime is a company developing online technology, which enables early diagnosis of diseases using real-time biometrics from the human body.
The Longevity InTime team includes experienced biotechnologists, award-winning scientists, developers, and experienced executives with years of experience. Together we are solving the global problem of life expectancy for each person and for all mankind.
Our goal is to extend a person's life by more than 20 active and happy years without any restrictions to him. We respond to both the personal and public interests of every country on Earth.Longevity Intime is a company developing online technology, which enables early diagnosis of diseases using real-time biometrics from the human body. The Longevity InTime team includes experienced biotechnologists, award-winning scientists, developers, and experienced executives with years of experience.
Patent Number : 411898 Date of Patent : 24/05/2014
Application Number : 10903/DELNP/2015 Date of Grant : 21/11/2022
Type of Application : PCT NATIONAL PHASE APPLICATION Date of Recordal : 21/11/2022
Parent Application Number : --- Appropriate Office : DELHI
PCT International Application Number : PCT/JP2014/063758 PCT International Filing Date : 24/05/2014
Grant Title : VERTICAL AXIS WATER/WIND TURBINE MOTOR USING FLIGHT FEATHER OPENING/CLOSING WING SYSTEM
Sl No Name of Grantee Grantee Type Grantee Address
1 TAMATSU Yoshiji NATURAL PERSON Room16Toyota Apartment1656 5Aza OrokuNaha shi Okinawa 9010152
Sl No Name of Patentee Patentee Type Address of Patentee
1 TAMATSU Yoshiji NATURAL PERSON Room16Toyota Apartment1656 5Aza OrokuNaha shi Okinawa 9010152
Address of Service : Tech Corp. International Strategist TCIS, lndia 5th Floor, Caddie Commercial Tower, Aerocity, New Delhi- 110037 India
Additional Address of Service : --
Priority Date : 25/05/2013
Year Due dates for Renewal CBR No CBR Date Renewal Amount Renewal Certificate No Date of Renewal Renewal Period:
Normal Due Date Due Date with Extension From To
3rd year 21/02/2023 21/08/2023 12919 21/03/2023 800 27207 21/03/2023 24/05/2016 24/05/2017
4th year 21/02/2023 21/08/2023 12919 21/03/2023 800 27208 21/03/2023 24/05/2017 24/05/2018
5th year 21/02/2023 21/08/2023 12919 21/03/2023 800 27209 21/03/2023 24/05/2018 24/05/2019
6th year 21/02/2023 21/08/2023 12919 21/03/2023 800 27210 21/03/2023 24/05/2019 24/05/2020
7th year 21/02/2023 21/08/2023 12919 21/03/2023 2400 27211 21/03/2023 24/05/2020 24/05/2021
8th year 21/02/2023 21/08/2023 12919 21/03/2023 2400 27212 21/03/2023 24/05/2021 24/05/2022
9th year 21/02/2023 21/08/2023 12919 21/03/2023 2400 27213 21/03/2023 24/05/2022 24/05/2023
10th year 24/05/2023 24/11/2023 12919 21/03/2023 2400 27214 21/03/2023 24/05/2023 24/05/2024
11th year 24/05/2024 24/11/2024 12919 21/03/2023 4800 27215 21/03/2023 24/05/2024 24/05/2025
12th year 24/05/2025 24/11/2025 12919 21/03/2023 4800 27216 21/03/2023 24/05/2025 24/05/2026
13th year 24/05/2026 24/11/2026 12919 21/03/2023 4800 27217 21/03/2023 24/05/2026 24/05/2027
14th year 24/05/2027 24/11/2027 12919 21/03/2023 4800 27218 21/03/2023 24/05/2027 24/05/2028
15th year 24/05/2028 24/11/2028 12919 21/03/2023 4800 27219 21/03/2023 24/05/2028 24/05/2029
16th year 24/05/2029 24/11/2029 12919 21/03/2023 8000 27220 21/03/2023 24/05/2029 24/05/2030
17th year -- -- -- -- -- -- -- -- --
18th year -- -- -- -- -- -- -- -- --
19th year -- -- -- -- -- -- -- -- --
20th year -- -- -- -- -- -- -- -- --
Sl No Date of Entry Particulars/Remarks
Information u/s 146 (Working of Patents)
Sl No Patent Number Year
1 411898
TITLE OF INVENTION VERTICAL AXIS WATER/WIND TURBINE MOTOR USING FLIGHT FEATHER OPENING/CLOSING WING SYSTEM
FIELD OF INVENTION MECHANICAL ENGINEERING
E-MAIL (As Per Record) prity.khastgir@gmail.com
ADDITIONAL-EMAIL (As Per Record)
E-MAIL (UPDATED Online) khasip@khastgir.com
PCT INTERNATIONAL APPLICATION NUMBER PCT
Dear Sir/ Madam,
Congratulations, you have been shortlisted for our next phase of audition of Shark Tank India, which is the In-Person Audition! At this stage of the audition our team will be meeting you in-person to further discuss your business/idea. Please note, we will be conducting these “In-Person Auditions” in Mumbai, Bengaluru, Delhi & Kolkata.
As per your form, your audition city is Delhi
Audition Venue: WelcomHotel ITC Dwarka, Plot No 3, District Center, Sector 10 Dwarka, New Delhi, Delhi 110075.
Landline - 01142229222
Location – Welcomhotel Dwarka offers easy access to the Delhi Metro Blue Line near by metro station Dwarka Sector 10. Located 20 minutes away from Indira Gandhi International Airport and the domestic airport in New Delhi.
Audition Date & Time: 15th July'22 Friday at 1pm
Time commitment required: 4 hours on the audition day
Kindly note the following guidelines for the in-person audition -
COVID Mandatory Safety Guidelines:
Applicants and any accompanying persons will need to wear a mask at all times and adhere to all the social distancing guidelines communicated by us, while at the venue
In case, you and any accompanying persons are vaccinated please carry your updated vaccination certificate (first and second dosage) or the Arogya Setu Pass.
In case you and any accompanying persons are not vaccinated, RT PCR Test with a 48 hour validity is mandatory and the status will be checked prior to at the venue.
A mandatory Rapid Antigen Test will be administered at the venue and only if the same turns out to be negative, will the applicant be allowed to proceed further.
Please note, that all applicants and any accompanying person will at all times have to comply with the rules and regulations mandated by the Central or State Government with respect to COVID 19 prevention issued at that time.
Documents for verification required at the time of audition: -
(Please note the documents are required for verification at the time of audition, kindly carry original copies too & also please do email us these documents scanned copies before the audition date and also get it on your pen drive at the venue also. Email us on - sharktankindia1@setindia.com)
Mandatory
Applicant’s Photo Identity proof & Address Proofs (Aadhar Card & Pan-Card)
Document proofs to validate accreditation & Audited Financials - Balance Sheets, Net worth Certificate (if any) and Income Statement for last 3 years. Please note, the certificate should be taken from the CA/CA Firm (on their letterhead)
Certificates evidencing any change of name, Memorandum of Association, Articles of Association, registered partnership deed, etc. or equivalent documents
No Objection Certificate (NOC), signed & dated, from all shareholders/co-founders/partners/investors
Company PAN CARD/GST Certificates
Income Tax Returns for the last 3 years (according to the business tenure)
If Applicable
Certificate of Incorporation or registration for your firm/partnership/LLP/company
#Node CC: Philippe RochePhilippe Roche : 2nd Connect
Founding & Managing Partner
The distinction between private equity (PE) and venture capital (VC)
They differ in:
- Their amounts of investment
- Types of firms they choose to invest in
- Timing of their involvement in a company's lifespan
- Equity they receive as a result of their investments.
VCs often invest $10M or less.
PEs often spend $50 million or more.
Early-stage startups are the focus of VCs.
PEs focus on seasoned businesses.
A small portion of the corporation is owned by VCs.
PEs purchase a controlling stake from the stockholders.
VCs research exit strategies and fast growth.
PEs consider scaling businesses to increase productivity and profits.
Examples
VC firms: Bessemer Venture Partners, Andreessen Horowitz, and Sequoia Capital
VC-backed businesses: Juul, Stripe, SpaceX, Waymon, and Ripple Labs
Private equity firms: The Blackstone Group Inc., CVC Capital Partners, and TPG Capital are
Companies with PE backing: EQ Office, Panera Bread, and Refinitiv
PEs and VCs are, of course, much more complicated than this.
Please feel free to remark with your observations.
#startups #entrepreneurship #venturecapital #investing #finance #crossborder #inovexus #startup #VC #earlystage
#galeshapley
#smartcontracts
Ms. Prity Khastgir (b. 26 Dec. 1984). Obtained B.A.Sc (Hons) in Applied Sciences specialising in Food technology from University of Delhi and M.Sc in Biotechnology and LLB from University of Rajasthan. Did Entrepreneurship course from Indian School of Business (ISB) sponsored by Goldman Sachs 10,000 Women Entrepreneurs Initiative. She is Certified Mediator for Commercial Disputes and Negotiator in India. Currently, she is working towards launching innovation hub in
domestic and international level.
She is passionate about technology, law and business on a global scale. Recently, she was invited by China Government for China International Big Data Expo 2018, Guiyang. She is active in international technology arena and recently participated in the 4th Annual Asia Pacific Spectrum Management Conference and in World Summit on the Information Society (WSIS) Forum 2018, Geneva.
Senior executive profile with featured publications: BBC World, Nature Group (Nature Reviews Drug Discovery), BusinessWorld, BioSpectrum Asia etc. Previous work experience with US Law Firm headquartered in Greater New York City Area. Problem solver and Business Strategist with 12+ yrs exp. Seasoned Patent Strategist with expertise in IP portfolio research, cross-border tech transactions, licensing agreements, product clearance, FTO opinion, patent infringement and invalidity, IPR R&D Consultancy.
Aligning and facilitating youth to be driven in the industry 4.0 era is her motto to take India’s GDP to next level. She is a guest faculty at IMT, Ghaziabad taking lectures on legal aspects of doing business in India and understanding the innovation ethos globally.
#ITU Guide to drive Citizens' engagement for #Innovation #OpenGeneva
https://www.itu.int/net4/wsis/forum/2020/en/Agenda
Julia Dallest
Chief Operation Officer
Open Geneva
Julia Dallest is the Chief Operation Officer at Open Geneva. After 4 years as a change management consultant in Paris, Julia worked 2 years for a humanitarian mission in Madagascar as a partnership manager. Wishing to continue her involvement in the associative world, Julia joined Open Geneva as a volunteer in 2018 and as Chief Operation Officer since 2019.
Cristina Bueti
Counsellor of ITU-T Study Group 20 “Internet of things (IoT) and smart cities and communities (SC&C)”
International Telecommunication Union
Cristina Bueti is the Counsellor of ITU-T Study Group 20 “Internet of things (IoT) and smart cities and communities (SC&C)” at the International Telecommunication Union (ITU). She is responsible for ITU-T's activities on IoT and smart sustainable cities. She is the ITU focal point for environment and climate change including e-waste management. She also serves as TSB focal point for Latin America.
Cristina Bueti graduated from the Faculty of Political Science, Law and International Cooperation and Development of the University of Florence, where she completed postgraduate studies in International Cooperation and Telecommunications Law in Europe. She also holds a specialization in Environmental Law with a special focus on Telecommunications.
In 2003, Ms. Bueti built on her academic credentials by completing a specialized course in peace keeping and international cooperation with special focus on telecommunications at the Faculty of Laws, University of Malta, before joining the International Telecommunication Union in Geneva in January 2004.
As part of the International Women's Day 2016, she was named as one of the twenty Geneva-based inspirational women working to protect the environment.
She has authored over 40 reports on telecommunication issues. A native Italian speaker, Cristina is also fluent in English, French and Spanish.
Thomas Diez
FabCity
Venezuelan Urbanist specialized in digital fabrication and its implications on the future cities and society. He is the co-founder and director of Fab Lab Barcelona at the Institute for Advanced Architecture of Catalonia (IAAC), and is a founding partner of the Fab City Global Initiative. He is also the director of the recently launched Master in Design for Emergent Futures at IAAC. Tomas has been appointed by The Guardian and Nesta as one of the top 10 digital social innovators to watch in 2013, and has been awarded by the Catalan ICT association as the entrepreneur of the year in 2014.
More from Prity Khastgir IPR Strategic India Patent Attorney Amplify Innovation (20)
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Welocme to ViralQR, your best QR code generator.ViralQR
Welcome to ViralQR, your best QR code generator available on the market!
At ViralQR, we design static and dynamic QR codes. Our mission is to make business operations easier and customer engagement more powerful through the use of QR technology. Be it a small-scale business or a huge enterprise, our easy-to-use platform provides multiple choices that can be tailored according to your company's branding and marketing strategies.
Our Vision
We are here to make the process of creating QR codes easy and smooth, thus enhancing customer interaction and making business more fluid. We very strongly believe in the ability of QR codes to change the world for businesses in their interaction with customers and are set on making that technology accessible and usable far and wide.
Our Achievements
Ever since its inception, we have successfully served many clients by offering QR codes in their marketing, service delivery, and collection of feedback across various industries. Our platform has been recognized for its ease of use and amazing features, which helped a business to make QR codes.
Our Services
At ViralQR, here is a comprehensive suite of services that caters to your very needs:
Static QR Codes: Create free static QR codes. These QR codes are able to store significant information such as URLs, vCards, plain text, emails and SMS, Wi-Fi credentials, and Bitcoin addresses.
Dynamic QR codes: These also have all the advanced features but are subscription-based. They can directly link to PDF files, images, micro-landing pages, social accounts, review forms, business pages, and applications. In addition, they can be branded with CTAs, frames, patterns, colors, and logos to enhance your branding.
Pricing and Packages
Additionally, there is a 14-day free offer to ViralQR, which is an exceptional opportunity for new users to take a feel of this platform. One can easily subscribe from there and experience the full dynamic of using QR codes. The subscription plans are not only meant for business; they are priced very flexibly so that literally every business could afford to benefit from our service.
Why choose us?
ViralQR will provide services for marketing, advertising, catering, retail, and the like. The QR codes can be posted on fliers, packaging, merchandise, and banners, as well as to substitute for cash and cards in a restaurant or coffee shop. With QR codes integrated into your business, improve customer engagement and streamline operations.
Comprehensive Analytics
Subscribers of ViralQR receive detailed analytics and tracking tools in light of having a view of the core values of QR code performance. Our analytics dashboard shows aggregate views and unique views, as well as detailed information about each impression, including time, device, browser, and estimated location by city and country.
So, thank you for choosing ViralQR; we have an offer of nothing but the best in terms of QR code services to meet business diversity!
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfPaige Cruz
Monitoring and observability aren’t traditionally found in software curriculums and many of us cobble this knowledge together from whatever vendor or ecosystem we were first introduced to and whatever is a part of your current company’s observability stack.
While the dev and ops silo continues to crumble….many organizations still relegate monitoring & observability as the purview of ops, infra and SRE teams. This is a mistake - achieving a highly observable system requires collaboration up and down the stack.
I, a former op, would like to extend an invitation to all application developers to join the observability party will share these foundational concepts to build on:
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
Encryption in Microsoft 365 - ExpertsLive Netherlands 2024Albert Hoitingh
In this session I delve into the encryption technology used in Microsoft 365 and Microsoft Purview. Including the concepts of Customer Key and Double Key Encryption.
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
Patent Landscape & Technical IP Report for Antibody Antigen based Medical Diagnostic Kits filed in India
1. Patent Landscape & Technical
IP Report for Antibody- Antigen
Based Medical Diagnostic Kits
Filed in India
2. List of Granted & Pending Patents before the
Indian Patent Office relating to Antibody
based Inventions including diagnostic kits,
process and methods to test the disease.
3. Granted Patents in Medical Device Sector in India
Antibody therapy based invention titled “ANTI-TRKA ANTIBODY” was granted a
patent by the Indian Patent Office (IPO) to LAY LINE GENOMICS S.P.A on
21/02/2014. The patent application was filed on /09/2010 bearing patent
application number 1861/MUMNP/2010 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI17)
MICROBIOLOGY. The identified IPC for the invention is C07K16/28, A61K39/395,
A61P25/00.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
4. ANTI-TRKA ANTIBODY
Antibodies and derivatives there of. An anti-TrkA antibody is provided that
comprises:
a) a variable heavy chain comprising a sequence selected from any of BXhVHl,
BXhVH2, BXhVH3, BXhVH4, BXhVH5, or HuVHWOv as shown in Figure la; or
from variants of any of said sequences and/or b) a variable light chain comprising
a sequence selected from any of BXhVLl, BXhVL2, BXhVL3, BXhVL4, BXhVL5,
BXhVL6, BXhVL7 or BXhVL8; as shown in Figure lb, or from variants of any of
said sequences.
TrkA-binding derivatives are also provided. Antibodies or derivatives of the present
invention are useful in a number of therapies, including pain therapy.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
5. Granted Patents in Medical Device Category in India
Medical diagnostic invention titled “A SYSTEM FOR DETECTING PATHOGENS
USING MICROBEADS CONJUGATED TO BIORECOGNITION MOLECULES”
was granted a patent by the Indian Patent Office (IPO) to FIO CORPORATION on
15/04/2016. The patent application was filed on 11/09/2008 16:06:14 bearing
patent application number 7695/DELNP/2008 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI17)
MICROBIOLOGY. The identified IPC for the invention is C12Q1/04.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
6. A SYSTEM FOR DETECTING PATHOGENS USING MICROBEADS
CONJUGATED TO BIORECOGNITION MOLECULES
A method and system are provided for the simultaneous detection and
identification of multiple pathogens in a patient sample. The sample is combined
with microbeads, which have been injected with quantum dots or fluorescent
dye and conjugated to pathogen-specific biorecognition molecules, such as
antibodies and oligonucleotides.
Treatment options may be determined based on the identities of the pathogens
detected in the sample.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
7. Granted
Patents in
Medical
Device
Category in
India
Test based invention titled “HIGH THROUGHPUT
TESTING FOR PRESENCE OF
MICROORGANISMS IN A BIOLOGICAL SAMPLE”
was granted a patent by the Indian Patent Office
(IPO) to STIRUS GLOBAL SOLUTIONS LIMITED
on 04/04/2014. The patent application was filed on
22/08/2008 bearing patent application number
7202/DELNP/2008 before the Indian Patent Office.
Field of invention identified by the patent examiner
relates to field of (FI17) MICROBIOLOGY. The
identified IPC for the invention is C12Q-1/68
8. HIGH THROUGHPUT TESTING FOR PRESENCE OF MICROORGANISMS IN A
BIOLOGICAL SAMPLE
Provided are methods and apparatus for high throughput testing of biological
samples that may or may not comprise microorganisms. The methods include the
use of a diagnostic multiplexing panel (DMP) specifically designed for the
simultaneous identification of a plurality of potential microorganisms that may be
present in the biological sample via a primer extension reaction directed a highly
conserved nucleic acid sequences in the microorganisms under test. The
biological sample is typically immobilised on a solid substrate at a first location
before being transferred to a second location for analysis using the DMP. The
methods and apparatus of the invention are particularly suited to diagnosis of the
presence of infectious pathogens in the biological sample, for example for
diagnosis of sexually transmitted infection. Figure 1 is the representative Figure.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
9. Granted Patents in Medical Device Category in India
Invention titled “A COMPOSITION COMPRISING A
PHOSPHATIDYLETHANOLAMINE BINDING PEPTIDE CONJUGATE” was
granted a patent by the Indian Patent Office (IPO) to BOARD OF REGENTS, THE
UNIVERSITY OF TEXAS SYSTEM on 23/08/2013. The patent application was filed
on 04/01/2008 bearing patent application number 130/DELNP/2008 before the
Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C07K16/00.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
10. A COMPOSITION COMPRISING A PHOSPHATIDYLETHANOLAMINE BINDING
PEPTIDE CONJUGATE
Disclosed are surprising discoveries concerning the role of anionic phospholipids
and amino phospholipids in tumor vasculature and in viral entry and spread, and
compositions and methods for utilizing these findings in the treatment of cancer
and viral infections.
Also disclosed are advantageous antibody, immunoconjugate and
duramycin-based compositions and combinations that bind and inhibit anionic
phospholipids and amino phospholipids, for use in the safe and effective treatment
of cancer, viral infections and related diseases.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
11. Granted Patents in Medical Device Category in India
Invention titled “ANTIBODIES OR FRAGMENTS THEREOF HAVING
SCLEROSTIN BINDING AND SCLEROSTIN NEUTRALIZING ACTIVITY” was
granted a patent by the Indian Patent Office (IPO) to 1.AMGEN INC. 2. UCB
PHARMA S.A. on 25/09/2015. The patent application was filed on 02/11/2007
bearing patent application number 4223/KOLNP/2007 before the Indian Patent
Office. Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C07K14/51.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
12. ANTIBODIES OR FRAGMENTS THEREOF HAVING SCLEROSTIN BINDING
AND SCLEROSTIN NEUTRALIZING ACTIVITY
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin
binding agents, such as antibodies capable of binding to sclerostin, are provided.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
13. Granted Patents in Medical Device Category in India
Medical kit based invention titled “SYNTHETIC PEPTIDE DERIVED FROM HIV
GAG P24 PROTEIN, ANTIGEN, VACCINE COMPOSITION AND KIT THEREOF”
was granted a patent by the Indian Patent Office (IPO) to BIONOR IMMUNO AS
on 06/01/2012. The patent application was filed on 11/09/2007 bearing patent
application number 1393/MUMNP/2007 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C07K14/16.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
14. SYNTHETIC PEPTIDE DERIVED FROM HIV GAG P24 PROTEIN, ANTIGEN,
VACCINE COMPOSITION AND KIT THEREOF
The present invention comprises novel and modified peptides capable of inducing
an HIV-1 specific immune response without antagonizing the cytotoxic T-cell
activity in order to achieve an effective prophylactic and therapeutic vaccine
against HIV. The peptides are based on conserved regions of HIV gag p24
proteins. Antigens in free or carrier-bound form comprising at least one of the said
peptides, vaccine compositions containing at least one of the antigens,
immunoassay kits and a method of detecting antibodies induced by HIV or HIV
specific peptides using such antigens, are described.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
15. Granted Patents in Medical Device Category in India
Invention titled “A SYNTHETIC PEPTIDE” was granted a patent by the Indian
Patent Office (IPO) to BIONOR IMMUNO AS on 06/07/2012. The patent
application was filed on 11/09/2007 bearing patent application number
1391/MUMNP/2007 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C07K-14/16.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
16. A SYNTHETIC PEPTIDE
The present invention comprises novel and modified peptides capable of inducing
an HIV-1 specific immune response without antagonizing the cytotoxic T-cell
activity in order to achieve an effective prophylactic and therapeutic vaccine
against HIV. The peptides are based on conserved regions of HIV gag p24
proteins. Antigens in free- or carrier-bound form comprising at least one of the said
peptides, vaccine compositions containing at least one of the antigens,
immunoassay kits and a method of detecting antibodies induced by HIV or HIV
specific peptides using such antigens, are described.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
17. Granted Patents in Medical Device Category in India
Peptide based invention titled “PEPTIDE OF SEQ ID NO. 15 DERIVED FROM
HIV GAG P24 PROTEIN, ANTIGEN AND VACCINE COMPOSITION THEREOF”
was granted a patent by the Indian Patent Office (IPO) to BIONOR IMMUNO AS
on 01/04/2011. The patent application was filed on 11/09/2007 bearing patent
application number 1392/MUMNP/2007 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C07K-14/16
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
18. PEPTIDE OF SEQ ID NO. 15 DERIVED FROM HIV GAG P24 PROTEIN,
ANTIGEN AND VACCINE COMPOSITION THEREOF
The present invention comprises novel and modified peptides capable of inducing
an HIV-1 specific immune response without antagonizing the cytotoxic T-cell
activity in order to achieve an effective prophylactic and therapeutic vaccine
against HIV. The peptides are based on conserved regions of HIV gag p24
proteins. Antigens in free- or carrier-bound form comprising at least one of the said
peptides, vaccine compositions containing at least one of the antigens,
immunoassay kits and a method of detecting antibodies induced by HIV or HIV
specific peptides using such antigens, are described.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
19. Granted Patents in Medical Device Category in India
Biotech invention titled “A PLASMID COMPRISING, AS THE SOLE YEAST
SELECTABLE MARKER,A GENE ENCODING A CHAPERONE,A HOST CELL
COMPRISING IT AND A METHOD OF PRODUCING...PROTEIN” was granted a
patent by the Indian Patent Office (IPO) to NOVOZYMES BIOPHARMA DK A/S on
09/09/2011. The patent application was filed on 25/06/2007 bearing patent
application number 2783/CHENP/2007 before the Indian Patent Office. Field of
invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C12N15/81.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
20. A PLASMID COMPRISING, AS THE SOLE YEAST SELECTABLE MARKER,A
GENE ENCODING A CHAPERONE,A HOST CELL COMPRISING IT AND A
METHOD OF PRODUCING PROTEIN
The present invention provides a method for producing a desired protein (such as
a desired heterologous protein) comprising: (a) providing a host cell comprising a
first recombinant gene encoding a protein comprising the sequence of a first
chaperone protein, a second recombinant gene encoding a protein comprising
the sequence of a second chaperone protein and a third gene, such as a third
recombinant gene, encoding a desired protein (such as a desired heterologous
protein), wherein the first and second chaperones are different; and (b) culturing
the host cell in a culture medium to obtain expression of the first, second and third
genes.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
21. Granted Patents in Pharma Sector in India
Invention titled “MODAFINIL MODIFIED RELEASE PHARMACEUTICAL
COMPOSITIONS” was granted a patent by the Indian Patent Office (IPO) to
CEPHALON, INC on 31/12/2010. The patent application was filed on 04/04/2006
bearing patent application number 812/KOLNP/2006 before the Indian Patent
Office.
Field of invention identified by the patent examiner relates to field of (FI11)
PHARMACEUTICALS. The identified IPC for the invention is A61K-9/20, &
A61K-9/26.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
22. MODAFINIL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS
Pharmaceutical compositions comprising modafinil. The pharmaceutical
compositions can have a release profile which is different than that of traditional
pharmaceutical compositions of modafinil.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
23. Granted Patents in Medical Device Category in India
Invention titled “A PURIFIED PROTEIN COMPRISING PHOSPHODIESTERASE
(PDE) CATALYTIC DOMAIN OR LEISHMANIA-PED-B1 AND USES THEREOF”
was granted a patent by the Indian Patent Office (IPO) to UNIVERSITY OF BERN
& OTSUKA PHARMACEUTICAL CO., LTD. on 14/01/2011. The patent application
was filed on 30/03/2006 bearing patent application number 773/KOLNP/2006
before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of
BIOTECHNOLOGY. The identified IPC for the invention is C07K-14/44.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
24. A PURIFIED PROTEIN COMPRISING PHOSPHODIESTERASE (PDE)
CATALYTIC DOMAIN OR LEISHMANIA-PED-B1 AND USES THEREOF
The present invention relates to novel amino acid and nucleic amino acid add
nucleic acid sequences of cyclic nucleotide-Specific phos-phodiesterses from the
parsite Lelskmmifa major. The invention also relates let nucleic acid consumers,
vectors, and host cells comprising the nucleic acid sequences as we'll as method
for producing and using the amino acid and nucleic and sequences. The invention
further relates to the use of these sequences , and of antibodies directed against
these.sequences, in the diagnosis treatment of disorders to the infection of Last
Monio major; including the identification of compounds than form complexes with
the polypeptides and nucleic acids of the present invention.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
25. Granted Patents in Medical Device Category in India
Invention titled “D-AMINO ACID PEPTIDES” was granted a patent by the Indian
Patent Office (IPO) to IMMUNOMEDICS INC on 13/02/2009. The patent
application was filed on 10/01/2006 bearing patent application number
125/CHENP/2006 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of
BIOCHEMISTRY. The identified IPC for the invention is C07K38/12.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
26. D-AMINO ACID PEPTIDES
The present invention provides compounds of the formula X-Rl-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn
or Lys](B)-R3(Y)-NR4R5; or Rl(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in
which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, Rl, R2 and R3 are independently
selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard
acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid
cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or
different, and R4 and R5 are independently selected from the group consisting of hard acid cation
chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H.
The present invention also provides methods of using these compounds and kits containing the
compounds.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
27. Granted Patents in Medical Device Category in India
Invention titled “A PROCESS FOR PREPARING PURE ARABINOSYL ATED
LIPOARABINOMANNAN EFFECTIVE AGAINST TUBERCULOSIS AND
LEISHMANIASIS” was granted a patent by the Indian Patent Office (IPO) to BOSE
INSTITUTE on 15/01/2010. The patent application was filed on 23/08/2005
bearing patent application number 772/KOL/2005 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI03)
CHEMICAL. The identified IPC for the invention is A61K-39/04.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
28. A PROCESS FOR PREPARING PURE ARABINOSYLATED LIPOARABINOMANNAN EFFECTIVE
AGAINST TUBERCULOSIS AND LEISHMANIASIS
Resurgence of Tuberculosis Mycobacteria resistant to Isoniazid (INH), PAS and
even Streptomycin (SM), and the parasite Leishmania donovani resistant to
classical antimonial drug SAG (sodium antimony gluconate) have been posing
problems, which have been claiming human lives, particularly in developing and
underdeveloped countries. This invention attempts to provide a therapeutic tool to
treat both Tuberculosis and Leishmaniasis and resides in a process for preparing
a glycolipid Ara-LAM in pure form which comprises isolating Ara-LAM from
Mycobacterium smegmatis, performing SDS- PAGE and silver staining showing
the specific 37 kDa band of Ara-LAM.
29. A PROCESS FOR PREPARING PURE ARABINOSYLATED LIPOARABINOMANNAN EFFECTIVE
AGAINST TUBERCULOSIS AND LEISHMANIASIS
Followed by purification characterized by (i) dialyzing overnight in PBS and
lyophilizing to dryness; (ii) dissolving the resulting powder in sterile PBS; (iii)
loading the solution in 50 ml Sephacryl-200 column and eluting with PBS
(Phosphate Buffer Saline) at pH 7.4; (iv) collecting the eluted fractions showing
maximum peak (through carbohydrate estimation by phenol-sulphuric acid
method) and lyophilizing the same; (v) repeating the step of column
chromatography using Tris Buffer containing 10 mM Tris and 0.15 NaC1 as eluent
at pH 7.4; (vi) collecting the eluted fractions showing maximum peak and
lyophilizing the same; (vii) dissolving the lyophilized powder in sterile double
distilled water; (viii) storing the solution at a low temperature of around -40°C for
further use and, if desired, (ix) converting the aqueous solution into orally or
intraperitoneally administrable vaccine by standard procedure.
30. Granted Patents in Medical Device Category in India
Invention titled “MODULAR ANTIGEN TRANSPORTER MOLECULES (MAT
MOLECULES) FOR MODULATING IMMUNE REACTIONS, ASSOCIATED
CONSTRUCTS” was granted a patent by the Indian Patent Office (IPO) to
IMVISION GMBH on 31/03/2008. The patent application was filed on 10/05/2005
bearing patent application number 397/MUMNP/2005 before the Indian Patent
Office.
Field of invention identified by the patent examiner relates to field of (FI15)
BIOCHEMISTRY.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
31. MODULAR ANTIGEN TRANSPORTER MOLECULES (MAT MOLECULES) FOR
MODULATING IMMUNE REACTIONS, ASSOCIATED CONSTRUCTS
A modular antigen transport molecule (MAT molecule) at least consisting of at
least one translocation module, at least one targeting module and at least one
antigen molecule, where
a)the translocation module is a molecular unit which brings about transport of the
MAT molecule from the extracellular space into the interior of the cell.,
b) the targeting module is a molecular unit which brings about transport of the
MAT molecule intracellularly to the organelles which are involved in the processing
of antigens or the loading of MHC molecules with antigens, and
c) the antigen module is a molecular unit which at least consists of one antigen
and which determines the specificity of an immune response modulated by the
MAT molecule in an individual.
32. Granted Patents in Medical Device Category in India
Invention titled “A COMPOUND OR A TARGETABLE CONSTRUCT FOR
THERAPEUTIC USE” was granted a patent by the Indian Patent Office (IPO) to
IMMUNOMEDICS INC on 21/09/2007. The patent application was filed on
13/12/2004 bearing patent application number 2815/CHENP/2004 before the
Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is A61K-47/48.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
33. A COMPOUND OR A TARGETABLE CONSTRUCT FOR THERAPEUTIC USE
The present invention relates to targetable constructs which may be bound by a
bispecific antibody or antibody fragment having at least one arm that specifically
binds a targeted tissue and at least one other arm that specifically binds the
targetable construct. The targetable construct comprises a carrier portion which
comprises or bears at least one epitope recognizable by at least one arm of said
bispecific antibody or antibody fragment.
The targetable construct further comprises one or more therapeutic or diagnostic
agents or enzymes. The invention provides constructs and methods for producing
the targetable constructs and bi-specific antibodies or antibody fragments, as well
as methods for using them.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
34. Granted Patents in Medical Device Category in India
Invention titled “A NOVEL CONJUGATE” was granted a patent by the Indian
Patent Office (IPO) to MOLMED SPA on 04/07/2008. The patent application was
filed on 29/10/2004 bearing patent application number 2465/CHENP/2004 before
the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI15)
BIOCHEMISTRY. The identified IPC for the invention is A61K-47/48.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
35. A NOVEL CONJUGATE
A conjugate of il-12 and at least one tumor targeting moiety
containing the NGR motif.
36. Granted Patents in Medical Device Category in India
Method invention titled “PROCESS FOR THE ISOLATION AND PURIFICATION
OF HIGHER YIELD OF PROTEIN P17 OF HIV-1(SUBTYPE C)(A NON LIVING
PROTEIN)” was granted a patent by the Indian Patent Office (IPO) to
DEPARTMENT OF BIOCHEMISTRY,DELHI UNIVERSITY on 26/11/2010. The
patent application was filed on 16/06/2003 bearing patent application number
808/DEL/2003 before the Indian Patent Office. Field of invention identified by the
patent examiner relates to field of (FI03) CHEMICAL. The identified IPC for the
invention is A61K-48/00.
.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
37. PROCESS FOR THE ISOLATION AND PURIFICATION OF HIGHER YIELD OF
PROTEIN P17 OF HIV-1(SUBTYPE C)(A NON LIVING PROTEIN)
A simple and efficient method for hyper-expression in Escherichia coli and
purification of matrix protein, p17, of human immunodeficiency virus type 1
(HTV-1) of both B- and C-subtypes is described. DNA sequences encoding p1 7.
of B-and C-subtype were cloned from respective gag sequences. The gag
sequences were obtained by PCR amplification using DNA extracted from
peripheral blood lymphocytes of an HTV-1 infected patient from India. DNA
sequence analysis revealed that die sample contained gag sequences of both
HTV-1 B and C subtypes indicating dual infection.
38. PROCESS FOR THE ISOLATION AND PURIFICATION OF HIGHER YIELD OF
PROTEIN P17 OF HIV-1(SUBTYPE C)(A NON LIVING PROTEIN)
A T7 promoter based expression system was optimised for hyper-expression of
pl7 iri the soluble form-Both pl7 (B- and C-subtype) were purified to near
homogeneity using conventional chromatographic techniques. Purification of pl7
(C subtype) was described for the first time with yield of 7.7 mg from one litre
culture. The yield of pl7 (B subtype) was 14.7 mg from one litre culture, which was
several folds better than reported earlier. The immunoreactivity of both types of pl7
to sera from HTV infected individuals was comparable. The method described
here provides large quantities of highly pure pl7 of both B and C subtype, which
can be used for structural, biochemical and immunologic^ characterization and,
eventually for diagnostic and prognostic applications.
39. Granted Patents in Medical Device Category in India
Peptide invention titled “PEPTIDE DERIVED FROM HIV-1 GAG P17 PROTEIN,
ANTIGEN AND VACCINE COMPOSITION” was granted a patent by the Indian
Patent Office (IPO) to BIONOR IMMUNO AS, on 24/10/2008. The patent
application was filed on 04/03/2003 bearing patent application number
00296/DELNP/2003 before the Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI11)
PHARMACEUTICALS.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
40. PEPTIDE DERIVED FROM HIV-1 GAG P17 PROTEIN, ANTIGEN AND VACCINE
COMPOSITION
The present invention comprises novel and modified peptides capable of inducing
a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity
in order to achieve an effective prophylactic and therapeutic vaccine against HIV.
The peptides are based on conserved regions of HIV gag p17 and p24 proteins.
Antigens in free- or carrier-bound form comprising at least one of the said
peptides, vaccine compositions containing at least one of the antigens,
immunoassay kits and a method of detecting antibodies induced by HIV or HIV
specific peptides using such antigens, are described.
41. Granted Patents in Medical Device Category in India
Invention titled “PEPTIDE DERIVED FROM HIV-1 REGULATORY PROTEIN,
ANTIGENS HAVING SAID PEPTIDES AND VACCINE COMPOSITION OF SAID
ANTIGEN” was granted a patent by the Indian Patent Office (IPO) to BIONOR
IMMUNO AS on 31/07/2009. The patent application was filed on 03/03/2003
bearing patent application number 00285/DELNP/2003 before the Indian Patent
Office.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
42. PEPTIDE DERIVED FROM HIV-1 REGULATORY PROTEIN, ANTIGENS
HAVING SAID PEPTIDES AND VACCINE COMPOSITION OF SAID ANTIGEN
The present invention comprises novel and modified peptides capable of inducing
a HlV-1 specific immune response without aniagon ing: the cytotoxic T-cell activity
in order to achieve an effective prophylactic and ihcrapcuiic vaccine apainsi IMV,
The peptides. arc based on Conserved regions of IPV Tai and Ruv. ruguiaiory
protein and NCF auxiliary proteins. Antigens in lron-or-or carrier-hound 1'orm
comprising at least one of the said peptides, vaccine compositions containing ui
leasi one of the antigens, immunoassay kits and a method of detecting antibodies
induced by HIV or HTV specific peptides using such antigens, arc described.
43. Granted Patents in Medical Device Category in India
Invention titled “A POLYNUCLEOTIDE HAVING THE NUCLEIC ACID
SEQUENCE ACCORDING TO SEQ ID NO:1, 2 OR 3 OR A SEQUENCE FROM
THE NUCLEOTIDE NUMBERS” was granted a patent by the Indian Patent Office
(IPO) to GENEART AG on 12/03/2010. The patent application was filed on
23/04/2002 bearing patent application number IN/PCT/2002/507/KOL before the
Indian Patent Office.
Field of invention identified by the patent examiner relates to field of (FI02)
BIOTECHNOLOGY. The identified IPC for the invention is C12N-15/49
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
44. A POLYNUCLEOTIDE HAVING THE NUCLEIC ACID SEQUENCE ACCORDING
TO SEQ ID NO:1, 2 OR 3 OR A SEQUENCE FROM THE NUCLEOTIDE
NUMBERS
A polynucleotide having the nucleic acid sequence according to SEQ ID NO:1, 2
or 3 or a sequence from the nucleotide numbers 167 to 1654, 1447 to 4458, 5589
to 8168, 4403 to 4984, 4924 to 5214, 5426 to 5671, 8170 to 8790, 5195 to 5409,
7730 to 7821, 5334 to 5409 or 7730 to 7821, or a continuous sequence on a
polynucleotide from the nucleotide numbers 5195 to 5409 and 7730 to 7821, or
5334 to 5409 and 7730 to 7821, each referring to SEQ ID NO:1.
45. Granted Patents in Medical Device Category in India
Invention titled “PEPTIDE DERIVED FROM HIV GAG P24 PROTEIN AND
ANTIGEN, VACCINE COMPOSITION AND IMMUNOASSAY KIT COMPRISING
THE SAME” was granted a patent by the Indian Patent Office (IPO) to BIONOR
IMMUNO AS on 15/08/2008. The patent application was filed on 30/08/2001
bearing patent application number IN/PCT/2001/01023/MUM before the Indian
Patent Office.
Field of invention identified by the patent examiner relates to field of (FI11)
PHARMACEUTICALS. The identified IPC for the invention is C07K14/16
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
46. PEPTIDE DERIVED FROM HIV GAG P24 PROTEIN AND ANTIGEN, VACCINE
COMPOSITION AND IMMUNOASSAY KIT COMPRISING THE SAME
PEPTIDE DERIVED FROM HIV gag p24 PROTEIN AND ANTIGEN, VACCINE
COMPOSITION AND IMMUNOASSAY KIT COMPRISING THE SAME" The
present invention relates to peptide derived from HIV gag p24 protein,
characterized in that it comprises a modified amino acid sequence containing
modifications compared to the native sequence and selected from the amino acid
sequence ID. NO. 3, the terminal ends of the sequences may be free carboxyl- or
amino groups, amides, acyls, acetyls or salts thereof, two or more of the C ys
residues may form part of an intrachain- or interchain disulphide binding, a
-S-(CH2)p-S- or a -(CH2)p-bridge wherein p = 1-8 optionally intervened by one or
more heteroatoms such as O, N and S and/or the said peptide sequences are
immobilized to a solid support. The present invention also relates to antigen,
vaccine composition and immunoassay kit comprising the said peptide.
47. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
201618022317 Targeting Lipids 2016/06/29 Published
201617007938
OLIGONUCLEOTIDE PROBES
AND USES THEREOF
2016/03/07 Published
201617006126
CLAMP DEVICE FOR
MINIMALLY INVASIVE
PROCEDURES AND USES
THEREOF
2016/02/22 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
48. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1981/KOLNP/2015
ANTIBODIES OR
FRAGMENTS THEREOF
HAVING SCLEROSTIN
BINDING AND SCLEROSTIN
NEUTRALIZING ACTIVITY
2015/06/22 Published
5326/DELNP/2015
CHLORIN DERIVATIVE
USEFUL IN PHOTODYNAMIC
THERAPY AND DIAGNOSIS
2015/06/17 Published
3376/DELNP/2015
APTAMERS AND USES
THEREOF
2015/04/21 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
49. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
2769/KOLNP/2014
PEPTIDES DERIVED FROM
VIRAL PROTEINS FOR USE AS
IMMUNOGENS AND DOSAGE
REACTANTS
2014/12/01 Published
4012/CHE/2014
FABRIC BASED MULTIPLEXED
IMMUNOASSAY DEVICES FOR
RAPID DIAGNOSTIC TESTING
2014/08/17 Published
2385/MUM/2014
A DIAGNOSTIC APPARATUS
FOR TESTING AND EARLY
DETECTION OF HIV (HUMAN
IMMUNODEFICIENCY VIRUS)
VIRUS.
2014/07/24 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
50. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
3072/CHE/2014
METHODS OF UPSCALING
MESENCHYMAL STROMAL
CELL PRODUCTION,
COMPOSITIONS AND KIT
THEREOF
2014/06/24 Published
1188/MUMNP/2014
ANTI ADRENOMEDULLIN
(ADM) ANTIBODY OR ANTI
ADM ANTIBODY FRAGMENT
OR ANTI ADM NON IG
SCAFFOLD FOR USE IN
THERAPY OF AN ACUTE
DISEASE OR ACUTE
CONDITION OF A PATIENT
FOR STABILIZING THE
CIRCULATION
2014/06/13 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
51. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1192/MUMNP/2014
ANTI ADRENOMEDULLIN
(ADM) ANTIBODY OR ANTI
ADM ANTIBODY FRAGMENT
OR ANTI ADM NON IG
SCAFFOLD FOR REGULATING
THE FLUID BALANCE IN A
PATIENT HAVING A CHRONIC
OR ACUTE DISEASE
2014/06/13 Published
1191/MUMNP/2014
ANTI ADRENOMEDULLIN
(ADM) ANTIBODY OR ANTI
ADM ANTIBODY FRAGMENT
OR AN ANTI ADM NON IG
SCAFFOLD FOR USE IN
THERAPY
2014/06/13 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
52. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1189/MUMNP/2014
ANTI ADRENOMEDULLIN
(ADM) ANTIBODY OR ANTI
ADM ANTIBODY FRAGMENT
OR ANTI ADM NON IG
SCAFFOLD FOR PREVENTION
OR REDUCTION OF ORGAN
DYSFUNCTION OR ORGAN
FAILURE IN A PATIENT
HAVING A CHRONIC OR
ACUTE DISEASE OR ACUTE
CONDITION
2014/06/13 Published
2611/CHE/2014
DIAGNOSTIC TEST KIT FOR
MULTIANALYTE DETECTION
2014/05/27 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
53. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
10070/DELNP/2013
MODIFIED BIOTIN BINDING
PROTEIN FUSION PROTEINS
THEREOF AND APPLICATIONS
2013/11/22 Published
10065/DELNP/2013
MULTIPLE ANTIGEN
PRESENTING IMMUNOGENIC
COMPOSITION AND METHODS
AND USES THEREOF
2013/11/22 Published
3367/DEL/2013
HERBAL TOOTHPASTE FOR
PROTECTION OF TOTAL ORAL
HEALTH
2013/11/18 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
54. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1912/KOLNP/2013
MONOMERIC AND
MULTIMERIC
IMMUNOGENIC PEPTIDES
2013/06/13 Published
1697/MUM/2013
RAPID DETECTION OF
CANDIDA SPECIES OR
PATHOGENS AND TOXIN BY
LESS CYCLE OF
BIOCONJUGATE-NANO-PCR
2013/05/10 Published
889/MUMNP/2013
COMPOSITIONS AND
METHODS FOR ACTIVATING
EXPRESSION BY A
SPECIFIC ENDOGENOUS
MIRNA
2013/05/09 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
55. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1965/CHENP/2013
HUMAN FACILITATING
CELLS AND USES
THEREOF
2013/03/12 Published
9304/CHENP/2012
ALBUMIN DERIVATIVES
AND VARIANTS
2012/10/31 Published
6295/DELNP/2012
CD20 ANTIBODIES AND
USES THEREOF
2012/07/17 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
56. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
4511/DELNP/2012
"ORGANIC COMPOSITIONS TO
TREAT HSF1-RELATED
DISEASES"
2012/05/22 Published
3728/CHENP/2012
DIAGNOSTIC GEL
COMPOSITION METHOD
FOR MAKING A
DIAGNOSTIC GEL
COMPOSITION
2012/04/26 Published
3492/DELNP/2012
A CYTOLYTIC RTX-TOXIN
FROM GALLIBACTERIUM
ANATIS
2012/04/20 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
57. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
4749/KOLNP/2011
METHODS FOR IDENTIFICATION
OF SITES FOR IGG
CONJUGATION
2011/11/17 Published
8810/DELNP/2011 URINARY DEVICE 2011/11/12 Published
402/CHE/2011
TECHNOLOGY PLATFORM
USED TO DEVELOP
THERAPEUTIC VACCINES AND
DRUGS AGAINST HIV AND
OTHER AUTOIMMUNE
DISEASES
2011/02/11 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
58. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
426/KOLNP/2011
ANTIBODIES DIRECTED
AGAINST PYROGLUTAMATE
MONOCYTE
CHEMOATTRACTANT
PROTEIN-1 (MCP-1-N1PE)
2011/01/27 Published
1429/KOL/2010
A CLIA KIT FOR THE EARLY
DETECTION OF IGM
ANTIBODIES TO
CHIKUNGUNYA PRESENT IN
HUMAN SERUM OR PLASMA
2010/12/22 Published
4543/KOLNP/2010
METHOD OF DIAGNOSIS OF
INFECTION BY
MYCOBACTERIA AND
REAGENTS THEREFOR
2010/11/30 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
59. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
6298/DELNP/2010
SELECTED ANTIBODIES
BINDING TO ANIONIC
PHOSPHOLIPIDS &
AMINOPHOSPHOLIPIDS
AND THEIR USE IN
TREATING VIRAL
INFECTIONS AND CANCER
2010/09/06 Published
1861/MUMNP/2010
ANTI-TRKA ANTIBODIES
AND DERIVATIVES
THEREOF
2010/09/01 Published
1861/MUMNP/2010 ANTI-TRKA ANTIBODY 2010/09/01 Granted
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
60. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1909/CHE/2010
METHODS OF MAKING A DIAGNOSTIC
COMPOSITION AND COMPOSITIONS
THEREFROM
2010/07/05 Published
716/KOL/2010
AN IMPROVED CHEMILUMINESCENCE
IMMUNOASSAY KIT FOR SIMULTANEOUS
DETECTION OF HIV 1 AND HIV 2
ANTIBODIES AND HIV 1 P24 ANTIGEN IN
HUMAN SERUM AND PLASMA
2010/07/01 Published
681/KOL/2010
A FILTER DEVICE FOR THE SEPARATION
OF PLASMA OR SERUM FROM THE
WHOLE BLOOD FOR THE DIAGNOSTIC
ASSAY
2010/06/24 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
61. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
3165/DELNP/2010
'FLOW FOCUSING METHOD
AND SYSTEM FOR FORMING
CONCENTRATED VOLUMES
OF MICROBEADS, AND
MICROBEADS FORMED
FURTHER THERETO'
2010/05/05 Published
2527/CHENP/2010
“ENGINEERED PERTACTIN
VARIANTS FOR VACCINE
USE”
2010/04/29 Published
1981/CHENP/2010
MIRNA EXPRESSION IN
HUMAN PERIPHERAL BLOOD
MICROVESICLES AND USES
THEREOF
2010/04/08 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
62. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
2067/DELNP/2010
"COMPOSITION AND
METHODS USE FOR
ANTIBODIES AGAINST
SCLEROSTIN"
2010/03/23 Published
731/DELNP/2010 "ASSAYS" 2010/02/02 Published
8226/DELNP/2009
"METHODS AND
COMPOSITIONS FOR
TREATING ALLERGIC
DISEASES"
2009/12/16 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
63. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
6866/DELNP/2009
“IMPRINTED POLYMERIC
MATERIALS FOR BINDING
VARIOUS TARGETS SUCH AS
VIRUSES”
2009/10/27 Published
4647/DELNP/2009
"MICROFLUIDIC SYSTEM AND
METHOD TO TEST FOR
TARGET MOLECULES IN A
BIOLOGICAL SAMPLE"
2009/07/16 Published
1578/MUM/2009
A DIAGNOSTIC KIT FOR
SIMULTANEOUS SCREENING
OF HIV-1 AND HIV-2
ANTIBODIES AND ANTIGENS
IN HUMAN SERUM AND
PLASMA
2009/07/03 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
64. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
10654/DELNP/2008
"CD4 MIMIC PEPTIDES AND
THEIR USES"
2008/12/24 Published
4931/KOLNP/2008
GENE THERAPY FOR
AMYOTROPHIC LATERAL
SCLEROSIS AND OTHER
SPINAL CORD DISORDERS
2008/12/04 Published
2275/MUMNP/2008
APOLIPOPROTEIN
FINGERPRINTING
TECHNIQUE
2008/10/23 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
65. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
7968/DELNP/2008
METHODS AND COMPOSITIONS
FOR HIGHLY SENSITIVE
ANALYSIS OF MARKERS AND
DETECTION OF MOLECULES
2008/09/22 Published
4878/CHENP/2008 AFFINITY REGIONS 2008/09/15 Published
7695/DELNP/2008
"METHOD FOR DETECTING
PATHOGENS USING
MICROBEADS CONJUGATED TO
BIORECOGNITION MOLECULES"
2008/09/11 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
66. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
7695/DELNP/2008
"A SYSTEM FOR DETECTING
PATHOGENS USING
MICROBEADS CONJUGATED TO
BIORECOGNITION MOLECULES"
2008/09/11 Granted
7202/DELNP/2008
HIGH THROUGHPUT TESTING
FOR PRESENCE OF
MICROORGANISMS IN A
BIOLOGICAL SAMPLE
2008/08/22 Published
7202/DELNP/2008
HIGH THROUGHPUT TESTING
FOR PRESENCE OF
MICROORGANISMS IN A
BIOLOGICAL SAMPLE
2008/08/22 Granted
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
67. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1615/MUMNP/2008
COMPOUNDS FOR THE
INHIBITION OF INTEGRINS
AND USE THEREOF
2008/07/29 Published
1492/KOLNP/2008
MULTIPLE ANTIGENIC
PEPTIDE ASSAY FOR
DETECTION OF HIV OR SIV
TYPE RETROVIRUSES
2008/04/11 Published
2501/DELNP/2008
METHOD OF DIAGNOSIS OF
TUBERCULOSIS RELATED
IMMUNE RESTORATION
SYNDROME (IRS)
2008/03/25 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
68. Patent
Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
130/DELNP/2008
SELECTED ANTIBODIES AND DURAMYCIN
PEPTIDES BINDING TO ANIONIC
PHOSPHOLIPIDS AND AMINO
PHOSPHOLIPIDS AND THEIR USE IN
TREATING VIRAL INFECTIONS AND CANCER
2008/01/04 Published
130/DELNP/2008
"A COMPOSITION COMPRISING A
PHOSPHATIDYLETHANOLAMINE BINDING
PEPTIDE CONJUGATE"
2008/01/04 Granted
9025/DELNP/2007
"HIV PEPTIDES ANTIGENS, VACCINE
COMPOSITIONS, IMMUNOASSAY KIT AND
METHOD OF DETECTING ANTIBODIES
INDUCED BY HIV"
2007/11/23 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
69. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
2249/MUM/2007
A QUALITATIVE IN VITRO
DIAGNOSTIC KIT FOR
SIMULTANEOUS DETECTION
OF ANTI-HIV AND HCV
ANTIBODIES AND HBsAg
ANTIGENS
2007/11/13 Published
2248/MUM/2007
A QUALITATIVE IN VITRO
DIAGNOSTIC KIT FOR
SIMULTANEOUS DETECTION
OF ANTI-HIV ANTIBODIES
AND HBsAg ANTIGENS
2007/11/13 Published
4223/KOLNP/2007 BINDING AGENTS 2007/11/02 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
70. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
4223/KOLNP/2007
ANTIBODIES OR FRAGMENTS
THEREOF HAVING
SCLEROSTIN BINDING AND
SCLEROSTIN NEUTRALIZING
ACTIVITY
2007/11/02 Granted
1393/MUMNP/2007
HIV PEPTIDES OF SEQ ID NO.
4, ANTIGENS, VACCINE
COMPOSITIONS,
IMMUNOASSAY KIT AND A
METHOD OF DETECTING
ANTIBODIES INDUCED BY HIV
2007/09/11 Published
1393/MUMNP/2007
SYNTHETIC PEPTIDE DERIVED
FROM HIV GAG P24 PROTEIN,
ANTIGEN, VACCINE
COMPOSITION AND KIT
THEREOF
2007/09/11 Granted
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
71. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1392/MUMNP/2007
HIV PEPTIDES OF SEQ ID NO.
15, ANTIGENS, VACCINE
COMPOSITIONS,
IMMUNOASSAY KIT AND A
METHOD OF DETECTING
ANTIBODIES INDUCED BY HIV
2007/09/11 Published
1391/MUMNP/2007
HIV PEPTIDES OF SEQ ID NO
9, ANTIGENS, VACCINE
COMPOSITIONS,
IMMUNOASSAY KIT AND A
METHOD OF DETECTING
ANTIBODIES INDUCED BY HIV
2007/09/11 Published
1391/MUMNP/2007 A SYNTHETIC PEPTIDE 2007/09/11 Granted
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
72. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1392/MUMNP/2007
PEPTIDE OF SEQ ID NO. 15
DERIVED FROM HIV GAG
P24 PROTEIN, ANTIGEN
AND VACCINE
COMPOSITION THEREOF
2007/09/11 Granted
5739/DELNP/2007
FC FUSION CONSTRUCTS
BINDING TO
PHOSPHATIDYLSERINE AND
THEIR THERAPEUTIC USE
2007/07/24 Published
3059/CHENP/2007
CELL FREE BIOSYNTHESIS
OF HIGH-QUALITY NUCLEIC
& NBSP ACID AND USES
THEREOF
2007/07/10 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
73. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
2783/CHENP/2007
GENE EXPRESSION
TECHNIQUE
2007/06/25 Published
2783/CHENP/2007
A PLASMID COMPRISING AS
THE SOLE YEAST SELECTABLE
MARKER,A GENE ENCODING A
CHAPERONE, A HOST CELL
COMPRISING IT AND A
METHOD OF PRODUCING
PROTEIN
2007/06/25 Granted
4296/DELNP/2007
"SUBSTITUTED
AMINOPYRIDINES AND USES
THEREOF"
2007/06/06 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
74. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
1958/CHENP/2007
ANDROGRAPHOLIDE DERIVATIVES
TO TREAT VIRAL INFECTIONS
2007/05/08 Published
168/KOLNP/2007
METHOD FOR MODULATING GENE
EXPRESSION BY ALTERING THE
CPG CONTENT
2007/01/15 Published
2807/CHENP/2006
METHODS OF PREDICTING A
BENEFIT OF ANTIOXIDANT
THERAPY FOR PREVENTION OF
CARDIOVASCULAR DISEASE IN
HYPERGLYCEMIC PATIENTS
2006/07/31 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
75. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
893/MUMNP/2006
"DISEASE MANAGEMENT
SYSTEM"
2006/07/26 Published
2065/DELNP/2006
LIPOSOMES AND
LIPOSOMAL COMPOSITIONS
FOR VACCINATION AND
DRUG DELIVERY
2006/04/17 Published
812/KOLNP/2006
MODAFINIL MODIFIED
RELEASE PHARMACEUTICAL
COMPOSITIONS
2006/04/04 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
76. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent
Status in India
1048/DELNP/2006
"METHOD FOR PRODUCTION OF
BIORESORBABLE MICROPARTICLES,
MICROPARTICLES THUS OBTAINED
AND USE THEREOF"
2006/02/28 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
77. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
243/MUM/2006
ANTIGEN DETECTION
USING ANTIBODIES
2006/02/21 Published
488/DELNP/2006
"SPECIFIC HUMAN
ANTIBODIES"
2006/01/30 Published
485/DELNP/2006
"ANTIBODIES AND USES
THEREOF"
2006/01/30 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
78. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
838/MUM/2005
A RAPID DIAGNOSTIC TEST
KIT
2005/07/12 Published
2968/DELNP/2005
CYCLOPROPYL BETA-AMINO
ACID DERIVATIVES
2005/07/04 Published
397/MUMNP/2005
MODULAR ANTIGEN
TRANSPORTER MOLECULES
(MAT MOLECULES) FOR
MODULATING IMMUNE
REACTIONS, ASSOCIATED
CONSTRUCTS
2005/05/10 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
79. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
397/MUMNP/2005
MODULAR ANTIGEN
TRANSPORTER MOLECULES
(MAT MOLECULES) FOR
MODULATING IMMUNE
REACTIONS, ASSOCIATED
CONSTRUCTS
2005/05/10 Granted
175/DELNP/2005
"ANTIBODIES AND USES
THEREOF"
2005/01/17 Published
2815/CHENP/2004
A COMPOUND OR A
TARGETABLE CONSTRUCT
FOR THERAPEUTIC USE
2004/12/13 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
80. Patent Application
Number
Patent Title Patent Application
Date in India
Current Patent
Status in India
2815/CHENP/2004
A COMPOUND OR A
TARGETABLE CONSTRUCT FOR
THERAPEUTIC USE
2004/12/13 Granted
2465/CHENP/2004 A NOVEL CONJUGATE 2004/10/29 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
81. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
808/DEL/2003
" PROCESS FOR THE
ISOLATION AND
PURIFICATION OF HIGHER
YIELD OF PROTEIN P17 OF
HIV-1(SUBTYPE C)(A NON
LIVING PROTEIN)."
2003/06/16 Published
808/DEL/2003
" PROCESS FOR THE
ISOLATION AND
PURIFICATION OF HIGHER
YIELD OF PROTEIN P17 OF
HIV-1(SUBTYPE C)(A NON
LIVING PROTEIN)."
2003/06/16 Granted
00296/DELNP/2003
"PEPTIDE DERIVED FROM
HIV-1 GAG P17 PROTEIN,
ANTIGEN AND VACCINE
COMPOSITION"
2003/03/04 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
82. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
00296/DELNP/2003
"PEPTIDE DERIVED FROM HIV-1
GAG P17 PROTEIN, ANTIGEN
AND VACCINE COMPOSITION"
2003/03/04 Granted
00285/DELNP/2003
''HIV REGULATORY AND
AUXILIARY PEPTIDES ANTIGENS
VACCINE COMPOSITIONS
IMMUNOASSAY KIT AND A
METHOD OF DETECTING
ANTIBODIES INDUCED BY HIV"
2003/03/03 Published
00285/DELNP/2003
''PEPTIDE DERIVED FROM HIV-1
REGULATORY PROTEIN,
ANTIGENS HAVING SAID
PEPTIDES AND VACCINE
COMPOSITION OF SAID
ANTIGEN"
2003/03/03 Granted
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
83. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
IN/PCT/2002/1010/CHE
NUCLEIC ACIDS ENCODING
(POLY) PEPTIDES HAVING CHIPS
ACTIVITY
2002/07/01 Published
IN/PCT/2002/507/KOL
A POLYNUCLEOTIDE HAVING THE
NUCLEIC ACID SEQUENCE
ACCORDING TO SEQ ID NO:1, 2
OR 3 OR A SEQUENCE FROM THE
NUCLEOTIDE NUMBERS
2002/04/23 Granted
IN/PCT/2001/1639/CHE
METHOD FOR ENHANCED
PROTEIN STABILIZATION AND
PRODUCTION OF CELL LINES
USEFUL FOR PRODUCTION OF
SUCH STABILIZED PROTEINS
2001/11/23 Published
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
84. Patent Application
Number
Patent Title Patent
Application Date
in India
Current Patent Status
in India
IN/PCT/2001/01023/MUM
PEPTIDE DERIVED FROM
HIV GAG P24 PROTEIN
AND ANTIGEN, VACCINE
COMPOSITION AND
IMMUNOASSAY KIT
COMPRISING THE SAME
2001/08/30 Granted
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services
85. Medical Diagnostic Patent Research Services | IP
Research & Technology Intelligence
We help our medical device clients with technology
intelligence services which is helpful to develop IP strategies.
In addition we provide research support to finalise the
prototype of the
Medical diagnostic kits.
www.techcorplegal.com | Patent your Invention, Idea, & Innovation | Patent Validity Search or Patent Invalidity Services